Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.

Cancer Chemother Pharmacol 2018 01 8;81(1):217-222. Epub 2017 Nov 8.

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, USA.

Depletion of glutamine (Gln) has emerged as a potential therapeutic approach in the treatment of acute myeloid leukemia (AML), as neoplastic cells require Gln for synthesis of cellular components essential for survival. Asparaginases deplete Gln, and asparaginase derived from Erwinia chrysanthemi (Erwinaze) appears to have the greatest glutaminase activity of the available asparaginases. In this Phase I study, we sought to determine the dose of Erwinaze that safely and effectively depletes plasma Gln levels to ≤ 120 μmol/L in patients with relapsed or refractory (R/R) AML. Five patients were enrolled before the study was halted due to issues with Erwinaze manufacturing supply. All patients received Erwinaze at a dose of 25,000 IU/m intravenously three times weekly for 2 weeks. Median trough plasma Gln level at 48 h after initial Erwinaze administration was 27.6 μmol/L, and 80% (lower limit of 1-sided 95% CI 34%) of patients achieved at least one undetectable plasma Gln value (< 12.5 μmol/L), with the fold reduction (FR) in Gln level at 3 days, relative to baseline, being 0.16 (p < 0.001 for rejecting FR = 1). No dose-limiting toxicities were identified. Two patients responded, one achieved partial remission and one achieved hematologic improvement after six doses of Erwinaze monotherapy. These data suggest asparaginase-induced Gln depletion may have an important role in the management of patients with AML, and support more pharmacologic and clinical studies on the mechanistically designed asparaginase combinations in AML.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3459-6DOI Listing
January 2018
48 Reads
2.770 Impact Factor

Publication Analysis

Top Keywords

plasma gln
12
effectively depletes
8
depletes plasma
8
myeloid leukemia
8
acute myeloid
8
erwinia chrysanthemi
8
gln
6
erwinaze
5
patients
5
relapsed refractory
4
≤ 120 μmol/l patients
4
refractory r/r
4
patients relapsed
4
patients enrolled
4
halted issues
4
issues erwinaze
4
erwinaze manufacturing
4
study halted
4
enrolled study
4
aml patients
4

References

(Supplied by CrossRef)

T Buchner et al.
J Clin Oncol 2012

E Estey et al.
Blood 2015

L Willems et al.
Blood 2013

N Jacque et al.
Blood 2015

A Emadi et al.
Cancer Chemother Pharmacol 2014

VI Avramis et al.
J Pediatr Hematol Oncol 2011

RL Capizzi et al.
J Clin Oncol 1988

T Ahmed et al.
Leuk Res 2015

A Emadi et al.
Pharmaceuticals (Basel) 2016

M Jarrar et al.
Pediatr Blood Cancer 2006

EH Panosyan et al.
Anticancer Res 2004

Similar Publications